Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Marijuana Abuse 2Breast Neoplasms 2Anxiety Disorders 2Sturge-Weber Syndrome 1Solid Tumor 1Prostatic Neoplasms 1Parasomnias 1Pain 1Nausea 1Glioblastoma 1Colonic Neoplasms 1Cognitive Dysfunction 1Chemotherapy-Induced Peripheral Neuropathy 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1Cancer Pain 1Breast Carcinoma In Situ 1Arthralgia 1

Interventions

Psilocybin 5Psychotherapy 2Fluoxetine 2Cannabidiol 2nabiximols 1Yoga 1Therapeutics 1Sertraline 1Self-Management 1Selective Serotonin Reuptake Inhibitors 1Professional Autonomy 1Pharmaceutical Preparations 1Niacin 1Neoadjuvant Therapy 1N-Methyl-3,4-methylenedioxyamphetamine 1Minocycline 1Medical Marijuana 1Ketamine 1Injections 1Hormones 1Gemcitabine 1Exercise 1Dronabinol 1Donepezil 1Clomipramine 1Citalopram 1Cisplatin 1Aromatherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Anxiety Disorders × Cannabidiol × Clear all
NCT03948074 2025-09-10

CAFCARS

British Columbia Cancer Agency

Phase 2 Completed
91 enrolled

Anxiety Disorders, Nausea, Pain, Parasomnias

NCT04482244 2025-07-29

RCT of CBD for Anxiety in Advanced Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
60 enrolled 11 charts

Anxiety Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡